Tumor derived EDIL3 modulates the expansion and osteoclastogenesis of myeloid derived suppressor cells in murine breast cancer model

Kun, Zhang; Gào, Xīn; Wang, Tao; Zhao, Chen; Wang, Dongsheng; Tang, Liang; Liu, Tielong; Xiao, Jianru

doi:10.1016/j.jbo.2019.100238

Cited by 13 publications

(11 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, MDSCs serve as osteoclast progenitors in breast cancer and enhance cancer-associated osteolysis. MDSCs differentiate into osteoclasts through NO signaling and cancer cells, thereby promoting osteolysis during bone metastasis in breast cancer, as reported in a murine model of breast cancer [49,146,147]. In breast cancer, the SDF-1/CXCR4 and CXCL5/CXCR2 axes recruit Gr-1 + CD11b + myeloid cells, activate MMP, and upregulate TGF-β1, which contributes to metastasis in mouse models injected with a breast cancer cell line (4T1) [124].…”

Section: Nonimmune Mechanism Of Mdscs In Breast Cancer Progression Anmentioning

confidence: 74%

Role of Tumor-Associated Myeloid Cells in Breast Cancer

Jin

Koo

2020

Cells

View full text Add to dashboard Cite

Stromal immune cells constitute the tumor microenvironment. These immune cell subsets include myeloid cells, the so-called tumor-associated myeloid cells (TAMCs), which are of two types: tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs). Breast tumors, particularly those in human epidermal growth factor receptor 2 (HER-2)-positive breast cancer and triple-negative breast cancer, are solid tumors containing immune cell stroma. TAMCs drive breast cancer progression via immune mediated, nonimmune-mediated, and metabolic interactions, thus serving as a potential therapeutic target for breast cancer. TAMC-associated breast cancer treatment approaches potentially involve the inhibition of TAM recruitment, modulation of TAM polarization/differentiation, reduction of TAM products, elimination of MDSCs, and reduction of MDSC products. Furthermore, TAMCs can enhance or restore immune responses during cancer immunotherapy. This review describes the role of TAMs and MDSCs in breast cancer and elucidates the clinical implications of TAMs and MDSCs as potential targets for breast cancer treatment.

show abstract

Section: Nonimmune Mechanism Of Mdscs In Breast Cancer Progression Anmentioning

confidence: 74%

Role of Tumor-Associated Myeloid Cells in Breast Cancer

Jin

Koo

2020

Cells

View full text Add to dashboard Cite

show abstract

“…Study showed that EDIL3 promoted tumors angiogenesis in vivo [14]. To determine whether EDIL3 also modulated dermal vascular network expansion in psoriatic mouse models, we conducted immuno uorescence analysis in skin sections and double immuno uorescence staining with DAPI and CD31 was evaluated via two-photon confocal laser microscopy.…”

Section: Edil3 Promoted Angiogenesis In Vivomentioning

confidence: 99%

“…The RGD motif can bind with integrin, then effect ECs functions including survival, adhesion, migration and angiogenesis [8,11,12]. During angiogenesis in early embryogenesis [13], tumor [14] and ischemic tissue [15], EDIL3 is an important molecular for mediating ECs functions. In present, whether EDIL3 derived from DMSCs can impact on ECs in psoriasis is unknown.…”

Section: Introductionmentioning

confidence: 99%

Regulation of Angiogenesis in Psoriasis by Dermal Mscs-Derived-EDIL3 via the Integrin Pathway

Niu

Han

et al. 2021

Preprint

View full text Add to dashboard Cite

One of the earliest events in the development of psoriatic lesion is a vascular network expansion. The abnormal vascular network is associated with increased endothelial cells (ECs) survival, proliferation, adhesion, migration, angiogenesis and permeability in psoriatic lesion. Recently, researchers found that the dermal mesenchymal stem cells (DMSCs) in psoriatic lesion involved in course of psoriasis. Our prior study demonstrated the mRNA and protein expression of the epidermal growth factor (EGF)-like repeats and discoidin I-like domains 3 (EDIL3) which is an important angiogenic and anti-inflammatory mediator in DMSCs was significantly upregulated in psoriasis. So, this study aimed to explore the association between DMSCs-derived-EDIL3 and psoriasis-associated angiogenesis in vivo and in vitro. In the present study, we confirmed that in vitro DMSCs-derived-EDIL3 involved in the adhesion, migration and tube formation of ECs via integrin-FAK/MEK/ERK signaling. In vivo, this research found that after injected recombination EDIL3 protein, the epidermis thickness and microvessel density were both elevated in the IMQ-induced psoriasis-like mouse model. Based on these results, we suggested that the modification of DMSCs, EDIL3 and integrin signal pathway might be a novel therapeutic strategy for psoriasis.

show abstract

“…When the steady state is not reached, a heterogeneous population of immature myeloid lineage cells, MDSCs, are produced [184]. Therefore, MDSCs are present in low concentration in healthy individuals, but as a result of chronic inflammation mediated by cytokines and chemokines produced by malignant cells, MDSCs are exponentially produced and accumulate in the tumor [185,186].…”

Section: Myeloid-derived Suppressor Cell Membrane-coated Npsmentioning

confidence: 99%

Biohybrid Nanosystems for Cancer Treatment: Merging the Best of Two Worlds

Fontana

Bártolo

Santos

2021

Advances in Experimental Medicine and Biology

View full text Add to dashboard Cite

During the last 20+ years, research into the biomedical application of nanotechnology has helped in reshaping cancer treatment. The clinical use of several passively targeted nanosystems resulted in improved quality of care for patients. However, the therapeutic efficacy of these systems is not superior to the original drugs. Moreover, despite extensive investigations into actively targeted nanocarriers, numerous barriers still remain before their successful clinical translation, including sufficient bloodstream circulation time and efficient tumor targeting. The combination of synthetic nanomaterials with biological elements (e.g., cells, cell membranes, and macromolecules) is presently the cutting-edge research in cancer nanotechnology. The features provided by the biological moieties render the particles with prolonged bloodstream circulation time and homotopic targeting to the tumor site. Moreover, cancer cell membranes serve as sources of neoantigens, useful in the formulation of nanovaccines. In this chapter, we will discuss the advantages of biohybrid nanosystems in cancer chemotherapy, immunotherapy, and combined therapy, as well as highlight their preparation methods and clinical translatability.

show abstract

Tumor derived EDIL3 modulates the expansion and osteoclastogenesis of myeloid derived suppressor cells in murine breast cancer model

Cited by 13 publications

References 42 publications

Role of Tumor-Associated Myeloid Cells in Breast Cancer

Role of Tumor-Associated Myeloid Cells in Breast Cancer

Regulation of Angiogenesis in Psoriasis by Dermal Mscs-Derived-EDIL3 via the Integrin Pathway

Biohybrid Nanosystems for Cancer Treatment: Merging the Best of Two Worlds

Contact Info

Product

Resources

About